| Oct 30 |
iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device
|
| Oct 30 |
iRhythm Technologies Non-GAAP EPS of -$1.26 misses by $0.69, revenue of $147.5M beats by $0.78M
|
| Oct 30 |
iRhythm Technologies Announces Third Quarter 2024 Financial Results
|
| Oct 29 |
iRhythm Technologies Q3 2024 Earnings Preview
|
| Oct 28 |
Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic Cardiomyopathy
|
| Oct 27 |
Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?
|
| Oct 23 |
iRhythm Technologies (IRTC) Soars 21.7%: Is Further Upside Left in the Stock?
|
| Oct 23 |
iRhythm’s Zio AT design changes win FDA clearance
|
| Oct 22 |
iRhythm Technologies: Today's 510(K) Victory May Only Be A Temporary Reprieve
|
| Oct 22 |
With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says
|
